Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

390

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

January 31, 2030

Conditions

Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

Interventions

DRUG

Glumetinib Tablets

An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor

DRUG

Osimertinib Mesylate Tablets

3rd EGFR-TKI

DRUG

Glumetinib Tablets Placebo

Placebo

All Listed Sponsors

lead

Shanghai JMT-Bio Inc.

INDUSTRY

NCT06908772 - Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients | Biotech Hunter | Biotech Hunter